Table 1.

Exclusion Criteria Related to VHD to Identify Patients With NVAF in DOAC Versus Warfarin Pivotal Trials

Exclusion Criteria	ROCKET‐AF	RE‐LY	ARISTOTLE	ENGAGE‐AF	AVERROES
Moderate or severe mitral stenosis	X		X	X
Prosthetic heart valve		X	X		X
Mechanical heart valve	X			X
Hemodynamically significant valve disease	X	X
VHD requiring surgery					X
Other conditions requiring anticoagulation	X		X		X
Unresected atrial myxoma				X

VHD indicates valvular heart disease; NVAF, nonvalvular atrial fibrillation; DOAC, direct oral anticoagulant; ROCKET‐AF, Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonist for Prevention of Stroke and Embolism Trial in Atrial Fibrillation; RE‐LY, Randomized Evaluation of Long Term Anticoagulation Therapy; ARISTOTLE, Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation; ENGAGE‐AF, Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation; AVERROES, Apixaban Versus Acetylsalicylic Acid to Prevent Strokes.